ALK and non-small cell lung carcinoma: Certain subsets of patients benefit from adjuvant tyrosine kinase inhibitors (TKIs) therapy (osimertinib in EGFR-mutated NSCLC (17)) or alectinib in ALK-mutated NSCLC (18), or adjuvant immunotherapy with immune-checkpoint inhibitors (ICI).